Jcr Pharmaceuticals Co., Ltd. · TSE:4552

Jcr Pharmaceuticals — FY2021 Earnings Presentation

19 slides from Jcr Pharmaceuticals's earnings presentation, May 12, 2022

  1. Slide 1: FY2021 Second-Half Results Briefing Session - Financial Results

    FY2021 Second-Half Results Briefing Session -Financial Results - May 12, 2022 JCR Pharmaceuticals Co., Ltd. 【Securities code】 4552, PRIME. TSE Copyright © 2022 JCR Pharmaceuticals Co., Ltd. All rights reserved.

  2. Slide 2: Financial Highlights (FY2021 Results)

    Financial Highlights (FY2021 Results) Net sales, operating income, ordinary income and profit have all reached record highs Net sales：51,082 million yen, Year-on-year +69.8％ Operating income：19,933 million yen, YoY +141.1％ Ordinary income：20,512 million yen, YoY +141.6％ Profit : 14,507 million yen,

  3. Slide 3: Consolidated Results

    Consolidated Results (Unit: million yen) FY2021 Reference ◆Operating income 19,933 million yen FY2020 (Apr. 1, 2021-Mar. 31, 2022) Year-on-year: +11,664 million yen (Apr. 1, 2020- Consolidated Year-on- Forecast Mar. 31, 2021) A B year (after (B-A)/A revision) 2021年3月期 FY2020 8,269 Net sales 30,085 5

  4. Slide 4: Breakdown of net sales (Consolidated)

    Breakdown of net sales (Consolidated) ◆Net sales 51,082 million yen (Unit: million yen) Year-on-year: +20,996 million yen FY2020 FY2021 Reference (Apr. 1, 2020- Mar. 31, 2021) (Apr. 1, 2021-Mar. 31, 2022) 2021年3月期 FY2020 30,085 Forecast グロウジェクト GROWJECT (311) Composition Composition Year-on-year (af

  5. Slide 5: Net Sales Trends by Product

    Net Sales Trends by Product Recombinant human growth hormone product (Unit: million yen) Recombinant erythropoietin product Long-acting erythropoiesis-stimulating agent GROWJECT® Epoetin Alfa BS Inj. [JCR] Darbepoetin Alfa BS Inj. [JCR] 13,256 エポエチンアルファ Epoetin Alfa ダルベポエチン Darbepoetin Recent topics

  6. Slide 6: IZCARGO Monthly Sales Trends

    IZCARGO® Monthly Sales Trends (Unit: million yen) Full Year 3,003 (2H total 2,017) 399 Topics 239 • Nov. 2020: Establishment of a dedicated team for 319 lysosomal storage disorders (LSDs) within the Marketing 407 Department to provide professional support for 339 information provision （上半期計 (1H tota

  7. Slide 7: Net Sales Trends (Excluding AZD1222 Bulk Solution)

    Net Sales Trends（ Excluding AZD1222 Bulk Solution） 製商品*売上高 Products* sales 契約金 License revenue (Unit: million yen) * Products: GROWJECT, IZCARGO, treatment for renal anemia, TEMCELL, Agalsidase Beta BS I.V. Infusion [JCR], others 10,571 6,406 2,050 3,560 2,137 26,134 22,731 23,275 18,457 19,600 2018

  8. Slide 8: Financial Status (Consolidated)

    Financial Status (Consolidated) (Unit: million yen) Mar. Mar. Change Mar. Mar. Change 2021 2022 ・ Main Increase/decrease 2021 2022 ・ Main Increase/decrease Total ＋13,025 ・ Special suspense account for Total ＋13,642 Current tax purpose reduction entry ・ Cash and deposits 29,028 42,054 liabilities ＋8,

  9. Slide 9: Cash Flows (Consolidated)

    Cash Flows (Consolidated) (Unit: million yen) 営業活動によるCF Operating Activities 投資活動によるCF Investing Activities End of Mar. 2021 End of Mar. 2022 Year-on-year Ａ Ｂ Ｂ-Ａ 財務活動によるCF Financing Activities 期末 現金及び現金同等物 Cash and Cash Equivalents at End of Period Income before income taxes 8,653 19,404 10,751 Dep

  10. Slide 10: Forecast Highlights (FY2022)

    Forecast Highlights (FY2022) Net sales： 45,000 million yen, Year-on-year (11.9)% Operating income： 14,500 million yen, YoY (27.3)% Ordinary income： 14,500 million yen, YoY (29.3)% Profit： 10,300 million yen, YoY (29.0)% ■ Sales and profit will decrease compared to FY2021 due to termination of the AZ

  11. Slide 11: FY2022 Forecast (Consolidated)

    FY2022 Forecast (Consolidated) (Unit: million yen) FY2021 FY2022 forecast Increase/ (Apr. 1, 2021- (Apr. 1, 2022- Year-on-year Consolidated decrease Mar. 31, 2022) Mar. 31, 2023) (B-A)/A A B Ｂ-Ａ Net Sales 51,082 45,000 (6,082) (11.9)% Cost of sales 10,461 9,000 (1,461) (14.0)% Gross profit 40,620 36

  12. Slide 12: FY2022 Forecast (Consolidated)

    FY2022 Forecast (Consolidated) (Unit: million yen) FY2021 FY2022 forecast (Apr. 1, 2021-Mar. 31, 2022) (Apr. 1, 2022-Mar. 31, 2023) Increase/ decrease Composition Composition (B-A) Ａ ratio Ｂ ratio GROWJECT® 12,945 25.3% 13,100 29.1% 154 IZCARGO® 3,003 5.9％ 5,210 11.6% 2,206 Treatments for renal 5,87

  13. Slide 13: Forward-Looking Statement

    FORWARD-LOOKING STATEMENT This presentation contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are outside our control. All forward-looking statements regarding our plans, outlook, strategy and future performance are based on judgments derived

  14. Slide 14: Copyright © 2022 JCR Pharmaceuticals Co., Ltd. All rights reserved.

    Copyright © 2022 JCR Pharmaceuticals Co., Ltd. All rights reserved.

  15. Slide 15: Reference: Trends in Sales Breakdown (Consolidated)

    Reference: Trends in Sales Breakdown (Consolidated) 23,898 (Unit: million yen) 8,046 AZD1222原液 AZD1222 bulk 14,834 51 404 6,329 その他 Other 11 契約金 License Revenue 7,557 16,721 アガルシダーゼ ベータBS Agalsidase Beta BS 8,817 6,396 9,084 3,014 テムセル TEMCELL 8,063 1,051 7 387 7,508 773 7,438 323 ダルベポエチン アルファBS Dar

  16. Slide 16: Reference: Trends in Composition Ratio of Cost/Expense

    Reference: Trends in Composition Ratio of Cost/Expense Operating income R&D expenses SG&A Costs of sales 営業利益 研究開発費 販売費・一般管理費 売上原価 20.5% 29.8% 28.4% 26.0% 31.9% 10,461 6,128 6,567 7,812 7,901 26.5% 28.7% 13,511 31.4% 31.4% 30.8% 8,643 6,469 7,270 7,638 14.0% 7,175 17.8% 18.8% 5,360 Above number (％)

  17. Slide 17: Reference: Forecast of Net Sales Trends by Product

    Reference: Forecast of Net Sales Trends by Product (Unit: million yen) Recombinant human growth hormone product Recombinant erythropoietin product Long-acting erythropoiesis-stimulating agent GROWJECT® Epoetin Alfa BS Inj. [JCR] Darbepoetin Alfa BS Inj. [JCR] エポエチンアルファ Epoetin Alfa ダルベポエチン Darbepoet

  18. Slide 18: Reference: Forecast of Net Sales Trends (Excluding AZD1222 Bulk Solution)

    Reference: Forecast of Net Sales Trends (Excluding AZD1222 Bulk Solution) 製商品*売上高 Products* sales 契約金 revenue License (Unit: million yen) * Products: GROWJECT, IZCARGO, treatment for renal anemia, TEMCELL, Agalsidase Beta BS I.V. Infusion [JCR], others 15,400 10,571 6,406 2,050 3,560 2,137 26,134 27

  19. Slide 19: Reference: Correlation between R&D Expenses and Main R&D Pipeline

    Reference: Correlation between R&D Expenses and Main R&D Pipeline (Unit: million yen) 9,500 Preclinical R&D Expenses (before deducting) 7,671 Clinical trial 6,582 5,856 5,270 Filed an application Approved FY2018 2019年3月期 FY2019 2020年3月期 FY2020 2021年3月期 FY2021 2022年3月期 FY2022 (forecast) 2023年3月期（予想）

JCR Pharmaceuticals — FY2021 Earnings Presentation on 6ix